The association of Treg and Th17 cells development factors and anti-TPO autoantibodies in patients with recurrent pregnancy loss.
Interleukin-17
Pregnancy loss
TGFβ
Th17
Thyroid autoimmunity
Tregs
Journal
BMC research notes
ISSN: 1756-0500
Titre abrégé: BMC Res Notes
Pays: England
ID NLM: 101462768
Informations de publication
Date de publication:
31 Oct 2023
31 Oct 2023
Historique:
received:
17
10
2022
accepted:
18
10
2023
medline:
2
11
2023
pubmed:
1
11
2023
entrez:
1
11
2023
Statut:
epublish
Résumé
Thyroid autoimmunity is considered as the most prevalent autoimmune condition in women in fertility age. There are different clinical evidences indicating the association between thyroid autoimmunity and increased risk of RPL. This study aimed to analyze the association of Tregs and Th17 cells development factors and anti-thyroid peroxidase (anti-TPO) antibodies in RPL patients. Healthy controls (n = 36), TPO + controls (n = 25) and TPO + RPL (n = 32) participated in this study. After blood sampling, the frequency of Th17 and Tregs was evaluated using flow cytometry. Real-time PCR and ELISA was used to assess the status of Tregs and Th17 related transcription factors and cytokines in mRNA and protein level, respectively. TPO + RPL group showed a higher Th17 frequency compared to healthy controls and TPO + controls groups (p = 0.0002 and p = 0.04, respectively). Additionally, mRNA expression levels of RORγT and IL-17 were significantly higher in TPO + RPL compared to healthy controls and TPO + controls groups. In contrast, Foxp3 and TGFβ expression was lower in TPO + RPL. ELISA findings also indicated a significantly higher IL-17 and lower TGFβ secretion in TPO + RPL compared to healthy controls and TPO + controls. Thyroid autoimmunity should intensely be controlled specially in patients with RPL history.
Identifiants
pubmed: 37907956
doi: 10.1186/s13104-023-06579-6
pii: 10.1186/s13104-023-06579-6
pmc: PMC10619307
doi:
Substances chimiques
Interleukin-17
0
Peroxidase
EC 1.11.1.7
Autoantibodies
0
Peroxidases
EC 1.11.1.-
Transforming Growth Factor beta
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
302Informations de copyright
© 2023. The Author(s).
Références
Am J Reprod Immunol. 2011 Feb;65(2):99-103
pubmed: 20618180
Reprod Biomed Online. 2014 Oct;29(4):481-9
pubmed: 25154016
J Reprod Immunol. 2010 Mar;84(2):164-70
pubmed: 20106535
Autoimmunity. 2008 Mar;41(2):154-62
pubmed: 18324485
J Reprod Immunol. 2019 Jun;133:18-26
pubmed: 31100644
Hum Reprod. 2011 Nov;26(11):2964-71
pubmed: 21926059
Iran J Allergy Asthma Immunol. 2020 Feb 01;19(1):65-73
pubmed: 32245322
Rev Obstet Gynecol. 2009 Spring;2(2):76-83
pubmed: 19609401
Iran J Reprod Med. 2012 Jul;10(4):373-6
pubmed: 25246900
Immunology. 2016 May;148(1):13-21
pubmed: 26855005
Am J Reprod Immunol. 2018 Sep;80(3):e12991
pubmed: 29923244
Am J Reprod Immunol. 2019 Oct;82(4):e13170
pubmed: 31310689
J Obstet Gynaecol Res. 2013 Jan;39(1):126-31
pubmed: 22889462
J Reprod Immunol. 2020 Nov;142:103182
pubmed: 32781360
J Nat Sci Biol Med. 2015 Jul-Dec;6(2):402-5
pubmed: 26283839
Int J Mol Sci. 2014 Nov 25;15(12):21674-86
pubmed: 25429429
Int Immunopharmacol. 2020 Oct;87:106806
pubmed: 32693358
Am J Reprod Immunol. 2020 Jun;83(6):e13238
pubmed: 32198952
J Reprod Immunol. 2020 Nov;142:103181
pubmed: 32717674